

ABC Committee meeting

Date: 15/11/16

Location: Manchester

Minutes: Confirmed

Committee members present:	
Tessa Lewis (TL) (Chair)	Section 1- 5
John Cape	Section 1- 5
Alison Eastwood	Section 1- 5
Sarah Fishburn	Section 1- 5
Gail Fortes Mayer	Section 1- 5
Catriona McDaid	Section 1- 5
Sophie Wilne (Vice Chair)	Section 1- 5
Maureen Daley (Topic Expert)	Section 1- 5
Rosemary Buck (Topic Expert)	Section 1- 5
John Graham (Topic Expert)	Section 1- 5

In attendance:		
Nitara Prasannan (NM)	Technical Analyst - NICE	Section 1- 5
Caroline Kier (CK)	Guideline Commissioning Manager - NICE	Section 1- 5
Nicole Elliott (NE)	Associate Director - NICE	Section 1 - 5
Hugh McGuire (HM)	Technical Advisor – NICE	Section 1 - 5
Martin Domanski (MD)	Project Manager – NICE	Section 1 - 5

Observers:	
Francesca Fasesin Technical Analyst – Surveillance	Section 1- 5
Alice Murray - Technical Analyst – Surveillance	Section 1- 5
David Tyldesley - Business Analyst - NICE	Section 1- 5

Apologies:

Victoria Hetherington – Standing Committee
--

Imran Jawaid – Standing Committee

Nick Screatton – Standing Committee

Karen McAdam – Topic Expert

Priya Bhagwat – Topic Expert

1. Welcome and objectives for the meeting
--

<p>The Chair welcomed the Committee members and attendees to the first meeting on Advanced Breast Cancer. The Committee members and attendees introduced themselves.</p>
--

<p>The meeting was opened to the public.</p>
--

<p>There were 2 public observers to the meeting.</p>
--

<p>The Chair informed the Committee that apologies had been received and they are listed above.</p>

<p>The Chair outlined the objectives of the meeting, which included discussing the review question: <i>In patients (women and men) with advanced breast cancer* and ER/PR/HER2 status known in primary tumour, does receptor status change on disease recurrence?</i></p>

<p><i>*Advanced breast cancer defined as invasive adenocarcinoma of the breast of clinical stage 4 (i.e. with known metastatic disease).</i></p>
--

2. Confirmation of matter under discussion, and declarations of interest

<p>The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was retesting receptor status in patients with advanced breast cancer.</p>
--

<p>The Chair and a senior member of the Developer's team noted that the interests declared did not prevent the attendees from fully participating in the meeting.</p>

3. Presentations

<p>The Chair introduced, Nitara Prasannan, technical analyst, who gave a brief overview of the topic and the parameters for the evidence review. The Chair took questions from the group. The Chair asked the Topic Specific lay member if she had</p>
--

anything to add. The member said it was interesting to hear about the difference between recurrence and advanced breast cancer and that she found the topic expert teleconference very helpful.

Nitara presented the review protocol for the review question. The Chair asked the topic experts to give their views on the review protocol outcomes. The committee discussed and agreed the critical outcomes to be used in the review protocol.

The Chair asked Nitara to present the clinical evidence for the review question. The Committee discussed the evidence and sought clarification to a number of queries from the NICE team. There was some discussion about the local recurrences and if they should be treated the same as distant metastases.

The Chair then asked Hugh McGuire, technical advisor, to present the economic evidence to the Committee.

The Chair closed the meeting to the public.

David Tyldesley from the Resource and Impact team briefly introduced role of his team and talked about the products they are developing.

The Chair asked Nitara to present the current recommendations to the committee. The committee discussed the recommendations and agreed any amendments to the guideline recommendations in light of the updated evidence.

4. Other issues

The Committee discussed the equality and diversity considerations related to the evidence for inclusion in the equality impact assessment form.

5. Next steps and any other business

Nicole Elliott presented the next steps in the process of updating of the guideline. The Chair thanked the Committee for their contribution to the meeting.

Meeting closed at 13.00

Date of next meeting: 24/04/2017

Location of next meeting: Manchester